New-onset diabetes mellitus type 2 treated with metformin - is it possible to slow the development of pancreatic cancer?- case report
New-onset DM2 and pancreatic cancer treated with metformin
DOI:
https://doi.org/10.12775/QS.2024.22.54304Keywords
pancreatic cancer, diabetes mellitus type 2, metformin, new-onset diabetes mellitus, cancer treatment, cancer diagnosisAbstract
In this article, we present the case of an 87-year-old patient whose initial symptom of developing pancreatic cancer was newly diagnosed type 2 diabetes mellitus. She was treated with metformin, which, on the one hand, could slow the development of pancreatic cancer and, on the other hand, delayed a key cancer diagnosis. However, before the definitive diagnosis, the patient's symptoms were considered merely as side effects of metformin treatment, delaying the proper diagnosis. We consider that early diagnosis of pancreatic cancer remains a significant challenge. Often, the first symptom is newly diagnosed diabetes mellitus type 2. In this article, we aim to demonstrate the importance of being vigilant when diagnosing and treating diabetes mellitus with metformin. We also present the impact of metformin on the course of pancreatic cancer. Additionally, we emphasize the need to be attentive when patients complain of side effects of this medication, as they may often mask the development of pancreatic cancer.
References
Gyawali M, Venkatesan N, Ogeyingbo OD, et al. Magic of a Common Sugar Pill in Cancer: Can Metformin Raise Survival in Pancreatic Cancer Patients? Cureus. 2021 Aug 5;13(8):e16916. doi: 10.7759/cureus.16916. PMID: 34367843; PMCID: PMC8343553.
Dąbrowski A. Choroby trzustki - postępy 2022/2023. Med. Prakt. 2023; 5: 78-84.
Wan G, Sun X, Li F, et al. Survival Benefit of Metformin Adjuvant Treatment For Pancreatic Cancer Patients: a Systematic Review and Meta-Analysis. Cell Physiol Biochem. 2018;49(3):837-847. doi: 10.1159/000493214. Epub 2018 Sep 5. PMID: 30184547.
New-onset diabetes: a clue to the early diagnosis of pancreatic cancer. www.pancreatic.org/new-onset-diabetes-a-clue-to-the-early-diagnosis-of-pancreatic-cancer/ (access: 2024.03.28).
Hu J, Fan HD, Gong JP, Mao QS. The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis. BMC Gastroenterol. 2023 Feb 24;23(1):50. doi: 10.1186/s12876-023-02671-0. PMID: 36829129; PMCID: PMC9951539.
Parisotto M, Vuong-Robillard N, Kalegari P, et al. The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells. Cancers (Basel). 2022 Nov 14;14(22):5597. doi: 10.3390/cancers14225597. PMID: 36428689; PMCID: PMC9688551.
Szymczak-Pajor I, Drzewoski J, Świderska E, et al. Metformin Induces Apoptosis in Human Pancreatic Cancer (PC) Cells Accompanied by Changes in the Levels of Histone Acetyltransferases (Particularly, p300/CBP-Associated Factor (PCAF) Protein Levels). Pharmaceuticals (Basel). 2023 Jan 12;16(1):115. doi: 10.3390/ph16010115. PMID: 36678613; PMCID: PMC9863441.
Kim J, Bae YJ, Kang HT. Metformin Use May Increase Risk of Pancreatic Cancer in Diabetic Women: An Analysis of the Korean National Health Insurance Service-National Health Screening Cohort Database. Korean J Fam Med. 2022 Sep;43(5):327-333. doi: 10.4082/kjfm.22.0005. Epub 2022 Sep 20. PMID: 36168905; PMCID: PMC9532184.
Popovic K, Smolović B, Martinović M, Vučković L. The Relationship between Diabetes Mellitus and Pancreatic Cancer-Diabetes Mellitus as a Red Flag for Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev. 2023 Mar 6;32(3):298-305. doi: 10.1158/1055-9965.EPI-22-0951. PMID: 36595658.
George S, Jean-Baptiste W, Yusuf Ali A, et al. The Role of Type 2 Diabetes in Pancreatic Cancer. Cureus. 2022 Jun 24;14(6):e26288. doi: 10.7759/cureus.26288. PMID: 35898377; PMCID: PMC9308974.
Ambe CM, Mahipal A, Fulp J, Chen L, Malafa MP. Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. PLoS One. 2016 Mar 11;11(3):e0151632. doi: 10.1371/journal.pone.0151632. PMID: 26967162; PMCID: PMC4788143
Flory J, Lipska K. Metformin in 2019. JAMA. 2019 May 21;321(19):1926-1927. doi: 10.1001/jama.2019.3805. PMID: 31009043; PMCID: PMC7552083.
Dujic T, Causevic A, Bego T, et al. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. Diabet Med. 2016 Apr;33(4):511-4. doi: 10.1111/dme.13040. Epub 2015 Dec 24. PMID: 26605869; PMCID: PMC5064645.
New-onset diabetes: an early sign of pancreatic cancer? www.cancer.gov/news-events/cancer-currents-blog/2021/pancreatic-cancer-diabetes-early-detection (access: 2024.03.24).
Bures J, Kohoutova D, Skrha J, et al.. Diabetes Mellitus in Pancreatic Cancer: A Distinct Approach to Older Subjects with New-Onset Diabetes Mellitus. Cancers (Basel). 2023 Jul 19;15(14):3669. doi: 10.3390/cancers15143669. PMID: 37509329; PMCID: PMC10377806.
Hahn S, Oh BJ, Kim H, et al. Anti-cancer effects of metformin in a 3D co-culture model of pancreatic ductal adenocarcinoma. Am J Cancer Res. 2023 May 15;13(5):1806-1825. PMID: 37293149; PMCID: PMC10244103.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Katarzyna Pochodowicz, Karolina Rogowska , Julia Zawistowska , Weronika Rutkowska-Kawalec, Jakub Kawalec , Angelina Lęgas, Joanna Smalira , Weronika Rogala, Bartosz Przybysz , Karolina Urbańska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 69
Number of citations: 0